DOSSIER · 13F-HR · Q2 2026

Tri Locum Partners LP

$813M in tracked AUM across 19 positions as of Q2 2026.

TL
CIK 0001826434 · last filed Jun 30, 2026
Total AUM
$813M
as of Q2 2026
Holdings
19
positions
Whale Score
70
70
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

Tri Locum Partners LP manages a concentrated portfolio totaling approximately $294.02 million as of the report date September 30, 2025. The firm employs a high-conviction investment strategy characterized by low diversification, holding only 13 positions. The portfolio experienced a contraction of 10.8% in total value, decreasing from $329.51 million in the previous quarter. This decline in value is likely attributable to a combination of market performance in held securi...

Key Holdings

The portfolio is dominated by mid-to-large cap healthcare companies, with the top five positions constituting over 65% of the total assets. The largest holding, United Therapeutics Corp (UTHR), represents 17.42% of the portfolio at $51.22 million. This is a new position, indicating a strong immediate conviction. The second and third largest positions, Merck & Co (MRK) at 12.76% and Axsome Therapeutics (AXSM) at 12.07%, are also significant allocations.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
JNJ
JOHNSON & JOHNSON
$108M425K13.3%
02
VRTX
VERTEX PHARMACEUTICALS INC
$100M202K12.3%
03
LLY
ELI LILLY & CO
$92M77K11.3%
04
K08588103
ASCENDIS PHARMA A/S
$69M259K8.5%
05
DXCM
DEXCOM INC
$55M820K6.8%
06
AXSM
AXSOME THERAPEUTICS INC.
$54M219K6.6%
07
G50871105
JAZZ PHARMACEUTICALS PLC
$53M222K6.6%
08
ELVN
ENLIVEN THERAPEUTICS INC
$44M867K5.4%
09
ARGX
ARGENX SE
$39M42K4.7%
10
MDGL
MADRIGAL PHARMACEUTICALS INC
$37M68K4.5%

Filing history

2026Q2Jun 30
$813M 14.1%
19 positionsView →
2026Q1Mar 31
$713M 7.5%
17 positionsView →
2025Q4Dec 31
$770M 161.9%
15 positionsView →
2025Q3Sep 30
$294M 10.8%
13 positionsView →
2025Q2Jun 30
$330M 69.1%
23 positionsLocked
2025Q1Mar 31
$195M 59.6%
22 positionsLocked
2024Q4Dec 31
$483M 15.7%
28 positionsLocked
2024Q3Sep 30
$417M 5.5%
20 positionsLocked
2024Q2Jun 30
$395M 37.2%
25 positionsLocked
2024Q1Mar 31
$288M 31.8%
27 positionsLocked
2023Q4Dec 31
$219M 30.1%
24 positionsLocked
2023Q3Sep 30
$313M 16.2%
61 positionsLocked
Showing 12 of 23